Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2023.04.043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases.
BMC Pulm Med
December 2024
Department of respiratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Background: Dupilumab inhibiting the signaling of interleukin(IL)-4 and IL-13 was recommended for the treatment of severe asthma in children ≥ 6 years old according to the Global Initiative for Asthma (GINA,2024).This study aimed to analyse the efficacy and safety of dupilumab in paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory disease in a real-world population.
Methods: We evaluated the medical records of paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory diseases, such as atopic dermatitis (AD) and allergic rhinitis (AR), receiving dupilumab treatment.
Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies.
Ann Acad Med Singap
November 2024
Department of Dermatology, Singapore General Hospital, Singapore.
Article Synopsis
- Several new therapies, including biologics and JAK inhibitors, have been approved for treating atopic dermatitis (AD) in Singapore since 2016, leading to an update of treatment guidelines for moderate-to-severe cases.
- A modified Delphi panel with 12 dermatologists conducted surveys to reach consensus on treatment statements, resulting in agreement on 43 statements across different treatment categories.
- The study highlights dupilumab and JAK inhibitors as potential first-line treatments for certain patients with moderate-to-severe AD, and indicates that further updates to the guidelines may be necessary as new information emerges.
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.
Curr Med Res Opin
December 2024
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Article Synopsis
- Moderate-to-severe atopic dermatitis (AD) significantly affects patients' quality of life, and advanced systemic therapeutics (AST) like dupilumab and upadacitinib are available but underutilized.
- A study of 3,076 patients in the U.S. found that 436 were eligible for AST treatment, and factors like private insurance and disease severity influenced their treatment initiation.
- Despite the availability of AST, many patients—47% of adolescents and 58% of adults—remain untreated, highlighting a need for greater advocacy and accessibility for those with severe AD.
One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.
Adv Ther
December 2024
Sanofi, Amsterdam, the Netherlands.
Introduction: Currently, limited data are available on long-term use of dupilumab to treat atopic dermatitis (AD) in a multinational real-world setting. The aim of this analysis was to report the interim 1-year data for patients with AD enrolled in the GLOBOSTAD registry, including treatment patterns, dupilumab effectiveness and safety, and healthcare burden.
Methods: GLOBOSTAD is an ongoing, 5-year, multinational, prospective, observational study of adult/adolescent (aged ≥ 12 years at baseline) patients with AD who initiated dupilumab in real-world settings according to their local country-specific prescribing guidelines.
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!